Approval · Notice of Compliance 25317 · 2021
PULMOZYME: Notice of Compliance 25317
Issued February 25, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25317
- Date
- February 25, 2021
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change in manufacturing process and new filling suite
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PULMOZYME | Not yet assigned | — |
Medicinal ingredients
- DORNASE ALFA 1 MG per ML